Treatment of subnormal bone mineral density
AssigneeGenelabs Technologies, Inc.
InventorKenneth E. Schwartz
Life of this patent
Estimating the term…
Abstract
A method of treating an individual to increase the individual's bone mineral density (BMD) is disclosed. The method includes co-administering a calcitonin-like agent and a DHEA-like agent. Also disclosed are methods for potentiating the effect of treatment with a calcitonin-like agent on BMD and for increasing BMD in an individual being treated with DHEA, e.g., for treatment of systemic lupus erythematosus (SLE).
Claims20
A method of treating an individual to increase the individual's bone mineral density (BMD), comprising:
- a) administering a calcitonin-like agent to the individual;
- and
- b) during the period of calcitonin-like agent administration, administering a dehydroepiandrosterone (DHEA)-like agent,
- wherein the amounts of calcitonin- and DHEA-like agents administered are, in combination, effective to increase BMD, and wherein the co-administration of calcitonin- and DHEA-like agents potentiates any increase in BMD achievable by administration of that amount of calcitonin-like agent alone.
A method of potentiating the effect of treatment with a calcitonin-like agent on bone mineral density (BMD) in an individual, comprising:
- during the period of calcitonin-like agent treatment, administering a dehydroepiandrosterone (DHEA) to the individual, in an amount of about 50 mg or more per day,
- wherein the administration of the DHEA potentiates any increase in BMD achievable by administration of that amount of calcitonin-like agent alone.
Dependencies are inferred from the claim text.